LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $4.69 and last traded at $4.70, with a volume of 709714 shares trading hands. The stock had previously closed at $4.81.
Analysts Set New Price Targets
Several research firms have recently commented on LFST. The Goldman Sachs Group lifted their price target on LifeStance Health Group from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Monday, March 4th. Jefferies Financial Group boosted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. Morgan Stanley restated an "overweight" rating and set a $10.00 price target on shares of LifeStance Health Group in a report on Monday, April 22nd. Finally, Barclays upped their price objective on LifeStance Health Group from $7.00 to $8.00 and gave the company an "underweight" rating in a report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, LifeStance Health Group currently has a consensus rating of "Hold" and a consensus price target of $8.80.
Read Our Latest Stock Report on LifeStance Health Group
LifeStance Health Group Price Performance
The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -9.92 and a beta of 1.23. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.20. The company's fifty day moving average is $6.07 and its two-hundred day moving average is $6.52.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. The firm had revenue of $300.44 million for the quarter, compared to the consensus estimate of $299.02 million. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. The company's quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.09) EPS. As a group, research analysts predict that LifeStance Health Group, Inc. will post -0.26 earnings per share for the current year.
Insider Buying and Selling
In other news, insider Danish J. Qureshi sold 12,965 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $5.93, for a total value of $76,882.45. Following the sale, the insider now directly owns 4,911,050 shares in the company, valued at $29,122,526.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other LifeStance Health Group news, insider Paula Cipollone sold 48,278 shares of the business's stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $7.22, for a total transaction of $348,567.16. Following the completion of the transaction, the insider now owns 239,915 shares in the company, valued at approximately $1,732,186.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Danish J. Qureshi sold 12,965 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the sale, the insider now directly owns 4,911,050 shares in the company, valued at $29,122,526.50. The disclosure for this sale can be found here. Insiders have sold a total of 4,100,681 shares of company stock valued at $24,087,326 in the last ninety days. Company insiders own 6.60% of the company's stock.
Hedge Funds Weigh In On LifeStance Health Group
A number of institutional investors and hedge funds have recently modified their holdings of the company. DekaBank Deutsche Girozentrale purchased a new stake in LifeStance Health Group during the 3rd quarter worth about $34,000. Sunbelt Securities Inc. purchased a new stake in LifeStance Health Group during the third quarter worth approximately $34,000. Bessemer Group Inc. lifted its stake in LifeStance Health Group by 43.4% during the first quarter. Bessemer Group Inc. now owns 9,143 shares of the company's stock worth $56,000 after purchasing an additional 2,768 shares during the last quarter. Assetmark Inc. boosted its holdings in LifeStance Health Group by 21.6% in the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company's stock valued at $93,000 after purchasing an additional 2,114 shares in the last quarter. Finally, Stratos Wealth Partners LTD. purchased a new position in LifeStance Health Group in the fourth quarter valued at approximately $93,000. Institutional investors and hedge funds own 85.50% of the company's stock.
About LifeStance Health Group
(Get Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
See Also
- Five stocks we like better than LifeStance Health Group
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Stock Impact: McDonald's Price War with Starbucks, Wendy's
- Stock Average Calculator
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Canada Bond Market Holiday: How to Invest and Trade
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
→ New Government Policy to Wipe Out Seniors Wealth (From Oasis Gold) (Ad)
Should you invest $1,000 in LifeStance Health Group right now?
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A Guide To High-Short-Interest Stocks
MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
